141 related articles for article (PubMed ID: 36602591)
1. Testosterone treatment and the risk of osteonecrosis: a pharmacovigilance analysis in Vigibase.
Vabre C; Johnson K; Montastruc F; Vezzosi D; Yu OH; Renoux C
Eur J Clin Pharmacol; 2023 Mar; 79(3):383-388. PubMed ID: 36602591
[TBL] [Abstract][Full Text] [Related]
2. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
Nguyen DD; Marchese M; Cone EB; Paciotti M; Basaria S; Bhojani N; Trinh QD
JAMA Dermatol; 2021 Jan; 157(1):35-42. PubMed ID: 33175100
[TBL] [Abstract][Full Text] [Related]
3. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database.
de Boissieu P; Kanagaratnam L; Abou Taam M; Roux MP; Dramé M; Trenque T
Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):989-92. PubMed ID: 24737486
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced tics: An observational postmarketing study.
Touafchia D; Montastruc F; Lapeyre-Mestre M; Rousseau V; Chebane L; Revet A
Hum Psychopharmacol; 2020 Jul; 35(4):e2734. PubMed ID: 32352603
[TBL] [Abstract][Full Text] [Related]
5. Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.
Gudin B; Ladhari C; Robin P; Laroche ML; Babai S; Hillaire-Buys D; Faillie JL
Therapie; 2020; 75(6):641-647. PubMed ID: 32418731
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database.
de Germay S; Montastruc F; Carvajal A; Lapeyre-Mestre M; Montastruc JL
Parkinsonism Relat Disord; 2020 Jan; 70():55-59. PubMed ID: 31865063
[TBL] [Abstract][Full Text] [Related]
7. Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase
Noseda R; Bedussi F; Gobbi C; Ceschi A; Zecca C
J Headache Pain; 2024 Jan; 25(1):10. PubMed ID: 38243189
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors and Venous Thromboembolism: An Analysis of the WHO Pharmacovigilance Database.
Allouchery M; Beuvon C; Pérault-Pochat MC; Roblot P; Puyade M; Martin M
Clin Pharmacol Ther; 2022 Jul; 112(1):164-170. PubMed ID: 35426120
[TBL] [Abstract][Full Text] [Related]
9. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach.
Hosohata K; Inada A; Oyama S; Furushima D; Yamada H; Iwanaga K
J Clin Pharm Ther; 2019 Feb; 44(1):49-53. PubMed ID: 30014591
[TBL] [Abstract][Full Text] [Related]
10. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
11. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced vitiligo: a case/non-case study in Vigibase
Anthony N; Bourneau-Martin D; Ghamrawi S; Lagarce L; Babin M; Briet M
Fundam Clin Pharmacol; 2020 Dec; 34(6):736-742. PubMed ID: 32246859
[TBL] [Abstract][Full Text] [Related]
13. Drug induced stuttering: pharmacovigilance data.
Trenque T; Morel A; Trenque A; Azzouz B
Expert Opin Drug Saf; 2021 Mar; 20(3):373-378. PubMed ID: 33337944
[No Abstract] [Full Text] [Related]
14. Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022.
Storck W; de Laportalière TT; Yrondi A; Javelot H; Berna F; Montastruc F
Psychopharmacology (Berl); 2024 Jun; 241(6):1205-1212. PubMed ID: 38376511
[TBL] [Abstract][Full Text] [Related]
15. Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database.
Zhao H; Li JM; Li ZR; Zhang Q; Zhong MK; Yan MM; Qiu XY
Front Pharmacol; 2023; 14():1182113. PubMed ID: 37502210
[No Abstract] [Full Text] [Related]
16. Cardiovascular Toxicities Associated With Ibrutinib.
Salem JE; Manouchehri A; Bretagne M; Lebrun-Vignes B; Groarke JD; Johnson DB; Yang T; Reddy NM; Funck-Brentano C; Brown JR; Roden DM; Moslehi JJ
J Am Coll Cardiol; 2019 Oct; 74(13):1667-1678. PubMed ID: 31558250
[TBL] [Abstract][Full Text] [Related]
17. Can tramadol really induce hyponatraemia? A pharmacovigilance study.
de Canecaude C; Rousseau V; Chebane L; Lafaurie M; Durrieu G; Montastruc JL
Br J Clin Pharmacol; 2021 Feb; 87(2):683-686. PubMed ID: 32470196
[TBL] [Abstract][Full Text] [Related]
18. Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.
Sagwa EL; Souverein PC; Ribeiro I; Leufkens HG; Mantel-Teeuwisse AK
Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):1-8. PubMed ID: 27868278
[TBL] [Abstract][Full Text] [Related]
19. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
20. Cataracts and statins. A disproportionality analysis using data from VigiBase.
Macías Saint-Gerons D; Bosco Cortez F; Jiménez López G; Castro JL; Tabarés-Seisdedos R
Regul Toxicol Pharmacol; 2019 Dec; 109():104509. PubMed ID: 31669197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
